Friday, March 7, 2025 **Conference Center – Ground Floor**

12:00 – 13:00	**Registration and Welcome Coffee**
13:30	**Welcome and introductory remarks** *Emanuele Zucca*
	Educational Lectures
	Chair: *Emanuele Zucca*
13:40 – 14:10	Epidemiology and treatment of lymphomas in China *Yuqin Song*
14:10 – 14:30	PMBCL treatment in children and adolescents *Véronique Minard-Colin*
	Primary Mediastinal B-Cell Lymphoma
	Chair: *Maurizio Martelli*
14:30 – 14:50	IELSG37 – Additional studies and manuscript in preparation on PMBCL imaging *Luca Ceriani*
14:50 – 15:10	Clinical utility of ctDNA *Vincent Camus*
15:10 – 15:20	IELSG55 – RWD analysis of R-CHOP-14 efficacy in the 1st line treatment of PMBCL *Anna Dabrowska & Vincent Camus*
15:20 – 15:40	Survey on the management of DS4 patients *Anastasios Stathis & David Hodgson*
15:40 – 16:10	General discussion of future potential IELSG study(ies) in PMBCL *Emanuele Zucca, Vincent Camus, Anastasios Stathis, David Hodgson*
16:10-16:30	**Coffee break**
	Marginal Zone Lymphoma I
	Chair: *Catherine Thieblemont*
16:30 – 16:50	MZL preclinical models *Victor Yazbeck*
16:50 – 17:00	IELSG39 – First-line *C. psittaci*-eradicating therapy with protracted doxycycline in Ocular Adnexal Marginal Zone Lymphoma: ancillary studies *Andrés JM Ferreri*
17:00 – 17:20	IELSG44 – PIMENTO - FDG-PET evaluation for marginal zone lymphoma and its prognostic role: an international multicenter retrospective analysis *Luca Ceriani*
17:20 – 17:35	IELSG47 – MALIBU – Phase II study of ibrutinib and rituximab in untreated marginal zone lymphoma: Preliminary results concerning the EMZL patients. *Annarita Conconi*
17:35 – 17:55	IELSG49 – Phase II trial of acalabrutinib in combination with tafasitamab in patients with previously treated marginal zone lymphomas *Anastasios Stathis*
17:55 – 18:05	IELSG53 – Phase III randomized study comparing targeted immunotherapy to rituximab plus chemotherapy in previously untreated, symptomatic MZL *Annarita Conconi*
	Primary and Secondary Lymphoma of the Central Nervous System
	Chair: *Franco Cavalli*
18:15 – 18:35	Present and Future IELSG Studies on CNS *Andrés JM Ferreri*
18:35 – 18:55	Proposal of a translational retrospective study on the multiomic characterization of PCNSL *Marco Lucioni, Marco Paulli*
19:30	**Dinner**

Closed Meeting	Saturday, March 8, 2025	
07:30 – 08:30	IELSG Board of Directors	Sala Camino

	Saturday, March 8, 2025	**Conference Center Ground Floor**
	Marginal Zone Lymphoma II	
	Chair: *Franco Cavalli*	
09:00 – 09:20	IELSG46 – Integrated molecular and clinical profiling to optimize outcome prediction in splenic marginal zone lymphoma: digital pathology review and morphological-molecular correlation *Lucia Bongiovanni*	
09:20 – 09:35	IELSG47 – MALIBU – Phase II study of ibrutinib and rituximab in untreated marginal zone lymphoma: Final analysis of the SMZL and NMZL cohorts *Catherine Thieblemont*	
09:35 – 09:55	IELSG48 – RITZ - Phase III, interventional, multicentre, open-label, randomized study comparing rituximab plus zanubrutinib to rituximab monotherapy in previously untreated, symptomatic splenic marginal zone lymphoma *Luca Arcaini*	
09:55 – 10:05	IELSG52 – Integrated molecular and clinical profiling to improve disease characterization and outcome prediction in nodal marginal zone lymphoma *Federico Jauk*	
10:05 – 10:15	IELSG54 – Integrated molecular and clinical profiling of transformed splenic marginal zone lymphoma *Emilia Cappello*	
10:15 – 10:30	Initial data of the Brazilian study on primary extranodal lymphomas (Primary Extranodal Lymphoma Effort - PELE) *Guilherme Duffles*	
	NK/T-cell Lymphoma	
	Chair: *Franco Cavalli*	
10:30 – 10:50	IELSG50 – Pembrolizumab and radiotherapy for limited-stage NK/T cell lymphoma *Stefano Luminari, Li Wang, Zhi-Ming Li*	
10:50 – 11:15	**Coffee break**	
11:15 – 12:00	***General Assembly***	**IELSG MEMBERS ONLY**
	Chair: *Franco Cavalli* Discussion of administrative issues	
12:00	Closing Remarks	

Thank you to all our sponsors for their generous support of this event.

INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP
Foundation for the Institute of Oncology Research
Via Vincenzo Vela, 6 | CH-6500 Bellinzona
Phone +41 58 666 73 21 | E-mail ielsg@ior.usi.ch | www.ielsg.org

Hotel La Palma

Conference Center – Gardenia Hall

Corso Umberto I n. 33 - 28838 Stresa